These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 34096596)

  • 1. Pharmacokinetic/pharmacodynamic evaluation of tobramycin dosing in critically ill patients: the Hartford nomogram does not fit.
    Xie F; Wang Y; Peng Y; Cheng Z; Li S
    J Antimicrob Chemother; 2021 Aug; 76(9):2335-2341. PubMed ID: 34096596
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacokinetic/pharmacodynamic-guided gentamicin dosing in critically ill patients: a revisit of the Hartford nomogram.
    He S; Cheng Z; Xie F
    Int J Antimicrob Agents; 2022 Jun; 59(6):106600. PubMed ID: 35533792
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Experience with a once-daily dosing program of aminoglycosides in critically ill patients.
    Buijk SE; Mouton JW; Gyssens IC; Verbrugh HA; Bruining HA
    Intensive Care Med; 2002 Jul; 28(7):936-42. PubMed ID: 12122533
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Tobramycin disposition in ICU patients receiving a once daily regimen: population approach and dosage simulations.
    Conil JM; Georges B; Ruiz S; Rival T; Seguin T; Cougot P; Fourcade O; Pharmd GH; Saivin S
    Br J Clin Pharmacol; 2011 Jan; 71(1):61-71. PubMed ID: 21143502
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A Simulated Application of the Hartford Hospital Aminoglycoside Dosing Nomogram for Plazomicin Dosing Interval Selection in Patients With Serious Infections Caused by Carbapenem-Resistant Enterobacterales.
    Asempa TE; Kuti JL; Seroogy JD; Komirenko AS; Nicolau DP
    Clin Ther; 2019 Aug; 41(8):1453-1462. PubMed ID: 31248681
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Evaluation of once daily tobramycin dosing in critically ill patients through Bayesian simulation.
    Peris-Marti JF; Borras-Blasco J; Rosique-Robles JD; Gonzalez-Delgado M
    J Clin Pharm Ther; 2004 Feb; 29(1):65-70. PubMed ID: 14748900
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Suboptimal aminoglycoside dosing in critically ill patients.
    Rea RS; Capitano B; Bies R; Bigos KL; Smith R; Lee H
    Ther Drug Monit; 2008 Dec; 30(6):674-81. PubMed ID: 19057371
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Development of a dosing nomogram for continuous-infusion meropenem in critically ill patients based on a validated population pharmacokinetic model.
    Minichmayr IK; Roberts JA; Frey OR; Roehr AC; Kloft C; Brinkmann A
    J Antimicrob Chemother; 2018 May; 73(5):1330-1339. PubMed ID: 29425283
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Population Pharmacokinetic Modeling and Dosing Simulations of Tobramycin in Pediatric Patients with Cystic Fibrosis.
    Praet A; Bourguignon L; Vetele F; Breant V; Genestet C; Dumitrescu O; Doleans-Jordheim A; Reix P; Goutelle S
    Antimicrob Agents Chemother; 2021 Sep; 65(10):e0073721. PubMed ID: 34280011
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Target concentration intervention is needed for tobramycin dosing in paediatric patients with cystic fibrosis--a population pharmacokinetic study.
    Hennig S; Norris R; Kirkpatrick CM
    Br J Clin Pharmacol; 2008 Apr; 65(4):502-10. PubMed ID: 17995972
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Monitoring of a single post-infusion blood sample to estimate the actual peak and trough concentration of tobramycin in critically ill patients.
    Reimann IR; Meier-Hellmann A; Traut T; Reinhart K; Hoffmann A
    Exp Toxicol Pathol; 2003 Jun; 54(5-6):493-8. PubMed ID: 12877363
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Role of renal function in risk assessment of target non-attainment after standard dosing of meropenem in critically ill patients: a prospective observational study.
    Ehmann L; Zoller M; Minichmayr IK; Scharf C; Maier B; Schmitt MV; Hartung N; Huisinga W; Vogeser M; Frey L; Zander J; Kloft C
    Crit Care; 2017 Oct; 21(1):263. PubMed ID: 29058601
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Validation of the Hartford nomogram in trauma surgery patients.
    Finnell DL; Davis GA; Cropp CD; Ensom MH
    Ann Pharmacother; 1998 Apr; 32(4):417-21. PubMed ID: 9562135
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Development and Evaluation of a Height-Based Tobramycin Initial Dosing Nomogram for the Treatment of Adult Cystic Fibrosis Pulmonary Exacerbations.
    El Hassani M; Thirion DJG; Koloskoff K; Matouk E; Simard C; Cloutier I; Pilote S; Marsot A
    Ther Drug Monit; 2023 Apr; 45(2):259-264. PubMed ID: 36730982
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Sub-optimal serum gentamicin concentrations in sickle cell disease patients utilizing the Hartford protocol.
    Abusham AA; Mohammed AH; Alkindi SS; Hassan MM; Al-Zakwani IS
    J Clin Pharm Ther; 2012 Apr; 37(2):212-6. PubMed ID: 21501204
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Tobramycin a Priori Dosing Regimens Based on PopPK Model Simulations in Critically Ill Patients: Are They Transferable?
    Duong A; Simard C; Williamson D; Marsot A
    Ther Drug Monit; 2023 Oct; 45(5):616-622. PubMed ID: 36917735
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Aminoglycosides in critically ill patients: which dosing regimens for which pathogens?
    Marsot A; Hraiech S; Cassir N; Daviet F; Parzy G; Blin O; Papazian L; Guilhaumou R
    Int J Antimicrob Agents; 2020 Oct; 56(4):106124. PubMed ID: 32739478
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The use of extended-interval aminoglycoside dosing strategies for the treatment of moderate-to-severe infections encountered in critically ill surgical patients.
    Mueller EW; Boucher BA
    Surg Infect (Larchmt); 2009 Dec; 10(6):563-70. PubMed ID: 20035611
    [TBL] [Abstract][Full Text] [Related]  

  • 19. External Validation of Model-Based Dosing Guidelines for Vancomycin, Gentamicin, and Tobramycin in Critically Ill Neonates and Children: A Pragmatic Two-Center Study.
    Hartman SJF; Orriëns LB; Zwaag SM; Poel T; de Hoop M; de Wildt SN
    Paediatr Drugs; 2020 Aug; 22(4):433-444. PubMed ID: 32507958
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Development of a dosing algorithm for meropenem in critically ill patients based on a population pharmacokinetic/pharmacodynamic analysis.
    Ehmann L; Zoller M; Minichmayr IK; Scharf C; Huisinga W; Zander J; Kloft C
    Int J Antimicrob Agents; 2019 Sep; 54(3):309-317. PubMed ID: 31229669
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.